Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Acceptable safety profile described for oral diflomotecan in solid tumors

Oct. 31, 2003

Targeted therapy of AML with anti-FLT3 antibody under evaluation

Oct. 30, 2003

Canadian approval for Gleevec for newly diagnosed Ph+ CML

Oct. 30, 2003

Sankyo intensifies development of anticancer drugs

Oct. 30, 2003

New inhibitors of ZAP-70, FAK and/or Syk designed at Novartis

Oct. 30, 2003

EN-3247 fails to prevent oral mucositis in pivotal trial

Oct. 29, 2003

Bay-43-9006 enters pivotal phase III trial in kidney cancer

Oct. 29, 2003

Yamanouchi describes new antitumor agents from Pseudomonas species

Oct. 29, 2003

Novel HDAC inhibitors isolated from a marine sponge by Yamanouchi scientists

Oct. 29, 2003

Steryl sulfatase inhibitors identified by Kyowa Hakko researchers

Oct. 29, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...